Allergy, Immunology and Rheumatology

Allergy, Immunology And Rheumatology Works in Progress

Allergy, Immunology, and Rheumatology

564 - IgE-mediated innate immune cell phenotypes correlate with SARS-CoV-2 antiviral CD4 T cell responses

568 - The effect of early peanut introduction on infant growth at age 2: Early evidence from the iREACH trial

WIP 152 - Differentiating primary and secondary T cell disorders using multiparametric flow cytometry

WIP 153 - Drug-Specific Presentations and Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review

WIP 154 - Evaluation of Perceptions of Early Peanut Introduction Among Parents

WIP 155 - Hemophagocytic Lymphohistiocytosis (HLH) in Children with Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): A Scoping Review

WIP 156 - Outcomes of a Penicillin Allergy Delabelling Initiative in a Pediatric Primary Care Center

WIP 157 - Pediatric DReSS: A Retrospective Study of Cyclosporine Treatment Outcomes

WIP 158 - Roles of peanut-specific B cell repertoires in determining clinical allergy or asymptomatic sensitization

556 - Are We Underdiagnosing SLE in Children Presenting with Psychiatric Manifestations?

557 - Association between maternal serum folic acid levels and onset of Kawasaki disease in offspring during infancy: The Japan Environment and Children’s Study

558 - Atopic Disease in Pediatric Patients with Ehlers-Danlos Syndrome

559 - Changes Over Three Months in Resilience Factors Among Youth with Chronic Musculoskeletal Pain and Their Caregivers Following Evaluation in an Interdisciplinary Pain Management Clinic

560 - Development of Respiratory Failure During Pediatric SARS-CoV-2 Infection is not Associated with Local or Systemic Antibody Responses

561 - Dupilumab significantly improves patient reported outcomes in pediatric AD patients less than 12 years of age

562 - Dupilumab Treatment Provides Sustained Improvement in Skin Barrier Function, Clinical Outcomes, and Patient-Reported Outcomes in Patients Aged 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis

563 - Efficacy and safety of dupilumab treatment up to 1 year in infants and preschool children with moderate-to-severe atopic dermatitis

565 - Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review

566 - Metabolic Programs for Neutrophil Disarray in a Mouse Model of Severe Malnutrition

567 - Penicillin allergy de-labeling: Adaptation of risk stratification tool for patients and families

569 - Variable long-term immune outcomes following SARS-CoV-2 vaccination in a diverse pediatric population

570 - With Equitable Treatment Children With Down Syndrome-Associated Arthritis Have Better Outcomes Compared to Juvenile Idiopathic Arthritis